-+ 0.00%
-+ 0.00%
-+ 0.00%

Genetic Analysis Q2 net loss widens to NOK 2.44 million; revenue falls 10.2% to NOK 5.29 million

PUBT·08/28/2026 06:01:00
Listen to the news
Genetic Analysis Q2 net loss widens to NOK 2.44 million; revenue falls 10.2% to NOK 5.29 million
  • Genetic Analysis posted Q2 2026 revenue of NOK 5.29 million, down 10.2% from Q2 2025.
  • EBITDA swung to a loss of NOK 998,000 from a profit in Q2 2025.
  • Net loss widened to NOK 2.44 million, while earnings per share deepened to NOK -0.04.
  • Gross margin rose to 91.2% from 73.7%, due to accruals for a refund of US customs duties.
  • CEO Ronny Hermansen cited progress on GA-map IBD Precision Dx toward a 2026 RUO launch, alongside expansion of the international lab network.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genetic Analysis AS published the original content used to generate this news brief via Cision (Ref. ID: 20260827:BIT:3217:0) on August 28, 2026, and is solely responsible for the information contained therein.